What Early Clinical Trials Have Told Us About Sotorasib

Apr 6, 2021

1 Min Watch

Mary J. Fidler, MD, Interviewee

Considering Whether Lurbinectedin May Improve Outcomes in SCLC

Combination Lurbinectedin & Checkpoint Inhibitors in the Treatment of SCLC

The Role of Trilaciclib As a Supportive Care Agent for SCLC Patients

Mary J. Fidler, MD, Associate Professor, Department of Internal Medicine, Division of Hematology, Oncology & Cell Therapy, Rush Medical College, Rush University Medical Center, elaborates on what early clinical trials have told us about the investigational product sotorasib.

© 2025 HealthCentral LLC. All rights reserved.

More Videos

2025’s Most Anticipated Advances in Lung Cancer

Eric K. Singhi, MD; Maya Khalil, MD; Sandip P. Patel, MD

Wave of FDA Approvals Marks Big Year for Lung Cancer

Maya Khalil, MD; Eric K. Singhi, MD; Sandip P. Patel, MD

“Unprecedented” Lung Cancer Data Drop: Now What?

Eric K. Singhi, MD; Sandip P. Patel, MD; Maya Khalil, MD

Top Lung Cancer Data From ASCO 2024

Sandip P. Patel, MD; Robert A. Figlin, MD, FACP

More Like This

2025’s Most Anticipated Advances in Lung Cancer

Eric K. Singhi, MD; Maya Khalil, MD; Sandip P. Patel, MD

2024 was packed with advances in lung cancer care. What will 2025 hold? The panel shares which potential breakthroughs they are most looking forward to seeing.

2025’s Most Anticipated Advances in Lung Cancer

Eric K. Singhi, MD; Maya Khalil, MD; Sandip P. Patel, MD

2024 was packed with advances in lung cancer care. What will 2025 hold? The panel shares which potential breakthroughs they are most looking forward to seeing.

Small Cell Lung Cancer (SCLC)

ASCO Updates Recommendations for SCLC

ASCO recently released a guideline rapid recommendation update for systemic therapy in patients with SCLC based on results of two key recent clinical trials.

Small Cell Lung Cancer (SCLC)

ASCO Updates Recommendations for SCLC

ASCO recently released a guideline rapid recommendation update for systemic therapy in patients with SCLC based on results of two key recent clinical trials.

Wave of FDA Approvals Marks Big Year for Lung Cancer

Maya Khalil, MD; Eric K. Singhi, MD; Sandip P. Patel, MD

Lung cancer treatment options greatly expanded this year. Our panel discusses 8 significant approvals by the FDA in “a year packed with lung cancer advancements.”

Wave of FDA Approvals Marks Big Year for Lung Cancer

Maya Khalil, MD; Eric K. Singhi, MD; Sandip P. Patel, MD

Lung cancer treatment options greatly expanded this year. Our panel discusses 8 significant approvals by the FDA in “a year packed with lung cancer advancements.”

Small Cell Lung Cancer (SCLC)

FDA Approves Durvalumab for Limited-Stage SCLC

The FDA approved durvalumab for adults with limited-stage small cell lung cancer who have not progressed after chemotherapy and radiation treatment.

Small Cell Lung Cancer (SCLC)

FDA Approves Durvalumab for Limited-Stage SCLC

The FDA approved durvalumab for adults with limited-stage small cell lung cancer who have not progressed after chemotherapy and radiation treatment.

Small Cell Lung Cancer (SCLC)

Big Year in SCLC: Clinical Highlights From 2024

2024 has been a big year for SCLC, with “astounding” results from a major clinical trial leading to a new standard of care among the significant developments.

Small Cell Lung Cancer (SCLC)

Big Year in SCLC: Clinical Highlights From 2024

2024 has been a big year for SCLC, with “astounding” results from a major clinical trial leading to a new standard of care among the significant developments.

Small Cell Lung Cancer (SCLC)

Data From "Astounding" SCLC Trial Raise Question

New data from the ADRIATIC trial shared at ESMO 2024 show a consistent OS benefit with durvalumab in LS-SCLC across subgroups but also contain a puzzling finding.

Small Cell Lung Cancer (SCLC)

Data From "Astounding" SCLC Trial Raise Question

New data from the ADRIATIC trial shared at ESMO 2024 show a consistent OS benefit with durvalumab in LS-SCLC across subgroups but also contain a puzzling finding.

“Unprecedented” Lung Cancer Data Drop: Now What?

Eric K. Singhi, MD; Sandip P. Patel, MD; Maya Khalil, MD

“Unprecedented” data in NSCLC and SCLC were presented at ASCO 2024. Our panelists explain what these findings mean for clinical practice in the short term.

“Unprecedented” Lung Cancer Data Drop: Now What?

Eric K. Singhi, MD; Sandip P. Patel, MD; Maya Khalil, MD

“Unprecedented” data in NSCLC and SCLC were presented at ASCO 2024. Our panelists explain what these findings mean for clinical practice in the short term.

Top Lung Cancer Data From ASCO 2024

Sandip P. Patel, MD; Robert A. Figlin, MD, FACP

Sandip P. Patel, MD, and Robert A. Figlin, MD, discuss top lung cancer data from ASCO 2024 that “should be incorporated into clinical practice immediately.”

Top Lung Cancer Data From ASCO 2024

Sandip P. Patel, MD; Robert A. Figlin, MD, FACP

Sandip P. Patel, MD, and Robert A. Figlin, MD, discuss top lung cancer data from ASCO 2024 that “should be incorporated into clinical practice immediately.”

Durvalumab Benefit in SCLC “Beyond” Expectations

Lauren Averett Byers, MD; Robert A. Figlin, MD, FACP

Lauren Averett Byers, MD, and Robert A. Figlin, MD, discuss data in LS-SCLC that show durvalumab’s benefit is “even beyond what we might have expected.”

Durvalumab Benefit in SCLC “Beyond” Expectations

Lauren Averett Byers, MD; Robert A. Figlin, MD, FACP

Lauren Averett Byers, MD, and Robert A. Figlin, MD, discuss data in LS-SCLC that show durvalumab’s benefit is “even beyond what we might have expected.”

'Groundbreaking' Data Upend Lung Cancer Practice

News that consolidation durvalumab will become the new standard of care for some patients with LS-SCLC was met with an extensive round of applause at ASCO 2024.

'Groundbreaking' Data Upend Lung Cancer Practice

News that consolidation durvalumab will become the new standard of care for some patients with LS-SCLC was met with an extensive round of applause at ASCO 2024.

FDA Approves Tarlatamab in Small Cell Lung Cancer

The FDA granted accelerated approval to tarlatamab in patients with SCLC after progression while on or after receiving platinum-based chemotherapy.

FDA Approves Tarlatamab in Small Cell Lung Cancer

The FDA granted accelerated approval to tarlatamab in patients with SCLC after progression while on or after receiving platinum-based chemotherapy.

Practice Change in SCLC? Durvalumab Ups Survival

Durvalumab improves survival in patients with limited-stage small cell lung cancer, according to new data from the ADRIATIC trial.

Practice Change in SCLC? Durvalumab Ups Survival

Durvalumab improves survival in patients with limited-stage small cell lung cancer, according to new data from the ADRIATIC trial.